title: Weekly gemcitabine and cisplatin chemotherapy: a well-tolerated but ineffective chemotherapeutic regimen in advanced pancreatic cancer patients. A report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD).
abstract: BACKGROUND
  This phase II study was initiated to determine the activity and toxicity of a combination of gemcitabine (GEM) and cisplatin (CDDP) in patients with pancreatic cancer.
  
  
  METHODS
  CDDP 35 mg/m(2) was given as a 30-min infusion and GEM 1000 mg/m(2) as a 30-min infusion. Both drugs were administered once weekly for 2 consecutive weeks out of every 3 weeks to chemonaive patients with locally advanced or metastatic pancreatic cancer.
  
  
  RESULTS
  Forty-five advanced pancreatic cancer patients received this regimen for a total of 180 cycles of chemotherapy. One complete and four partial responses have been observed for an overall response rate of 9% (95% confidence interval 10% to 11%). Twenty-one patients (46%) had stable disease and 19 progressed on therapy. The median time to progression was 3.6 months, with a median survival of 5.6 months. A clinical benefit was obtained in nine of 37 patients (24%). Side-effects were mainly represented by hematological toxicity. Grade 3/4 WHO toxicities included neutropenia (6% of the patients) and thrombocytopenia (11%). The dose of GEM and CDDP was reduced in 14 patients (31%) and treatment was delayed in 10 patients (22%).
  
  
  CONCLUSIONS
  Our results in terms of response rate, clinical benefit and survival do not support an advantage for the combination of GEM and CDDP given by this schedule.
authors.affiliation: Department and Unit of Medical Oncology, Parma, Italy. Cascinu@ yahoo.com
authors.forename: S
authors.initials: S
authors.lastname: Cascinu
authors.forename: R
authors.initials: R
authors.lastname: Labianca
authors.forename: V
authors.initials: V
authors.lastname: Catalano
authors.forename: S
authors.initials: S
authors.lastname: Barni
authors.forename: F
authors.initials: F
authors.lastname: Ferraù
authors.forename: G D
authors.initials: GD
authors.lastname: Beretta
authors.forename: L
authors.initials: L
authors.lastname: Frontini
authors.forename: P
authors.initials: P
authors.lastname: Foa
authors.forename: G
authors.initials: G
authors.lastname: Pancera
authors.forename: D
authors.initials: D
authors.lastname: Priolo
authors.forename: F
authors.initials: F
authors.lastname: Graziano
authors.forename: M
authors.initials: M
authors.lastname: Mare
authors.forename: G
authors.initials: G
authors.lastname: Catalano
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D002945:Cisplatin / Q000008:administration & dosage; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D018450:Disease Progression; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D008875:Middle Aged; D009503:Neutropenia / Q000139:chemically induced; D010166:Palliative Care; D010190:Pancreatic Neoplasms / Q000188:drug therapy* / Q000473:pathology; D013534:Survival; D013921:Thrombocytopenia / Q000139:chemically induced; D016896:Treatment Outcome; D000093542:Gemcitabine
chemical_list: D003841:Deoxycytidine; D002945:Cisplatin; D000093542:Gemcitabine